Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + Apatinib + Paclitaxel in Gastric Cancer
NCT03026881Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jan 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluzoparib in gastric cancer (GC), sponsored by Hengrui. Primary endpoint: Dose Limiting Toxicity at 6 months. Status: unknown.
02
Drugs
fluzoparib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03026881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03026881.